The pivotal phase 3 MANEUVER trial is a three-part, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety…
ASCO 2025
Results from the MATTERHORN phase 3 study demonstrate that immunotherapy in combination with standard chemotherapy before and after surgery significantly…
Results of the PANOVA-3 open-label, randomized phase 3 study show that compared with chemotherapy alone, the concomitant use of adding…
Final overall survival analysis from the phase 3 INAVO120 study demonstrates that first-line inavolisib in combination with standard-of care palbociclib-fulvestrant…
Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting* by Jaume Capdevila, a Medical Oncologist of the…
The BREAKWATER open-label, randomized phase 3 study was designed to evaluate first-line treatment with targeted therapies encorafenib and cetuximab plus…
